Fig. 4: Event-free survival of 260 patients with B-cell precursor ALL, classified according to patient-specific composition of all disease-relevant aberrations associated with prognostic significance in our patient cohort.

Excellent, good, high and ultra-poor risk groups showed an estimated 5-year EFS rate of 96.3%, 87.2%, 67.4% and 39.0%, respectively. Patient-specific scores were calculated as outlined in Table S6.